Mednet Logo

Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score? 

Community PollStarted

Which chemotherapy would you use in a young patient with ER+/PR+/HER2- node negative, intermediate grade breast cancer with high OncoType score?

260 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on

If this patient has a small, node negative, hormone receptor positive, HER2 negative intermediate grade tumor, I would be comfortable with recommending 4 cycles of adjuvant docetaxel and cyclophosphamide. Based on ABC trial results, the groups that benefited from AC-T regimen were patients with high...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester
Answered on · Updated on

For a node negative HR+ HER2- tumor in a pre-menopausal patient, I will usually recommend TC although I do discuss AC-T as well. This is based on the results of the ABC trial. Subset analysis of ABC suggested that the benefit for anthracyclines is largely derived by patients with triple negative can...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Warren Alpert Medical School of Brown University
Answered on

In the ABC analysis, patients with node-negative, ER+/HER2- cancers (Blum et al., PMID 28398846) actually did worse when they received an anthracycline in addition to TC (HR 0.69 for TC vs. TaxAC).

Join for free or sign in to see the full answer